Open AccessHigh Expression of PEA15 Is Associated With Patient Survival in Malignant Pleural Mesothelioma
Author(s) -
Saidul Islam,
Takao Kitagawa,
Yasuhiro Kuramitsu
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10049
Subject(s) - medicine , mesothelioma , biomarker , immunohistochemistry , oncology , mesothelium , overall survival , cancer , cancer research , pathology , mesothelial cell , biology , biochemistry
Malignant pleural mesothelioma (MPM) is a rare but very aggressive tumor that is primarily pleural in origin. The 5-year overall survival rate of patients with MPM has not improved despite therapeutic advances. Therefore, biomarker discovery to identify premalignant or early malignant tumors of the mesothelium are crucial. PEA15 is a cytoplasmic protein that is involved in various human malignancies, including MPM. However, the clinicopathological involvement of PEA15 in MPM has not yet been documented.